Brought to you by 
Apricus reverse merges with Seelos to focus on CNS therapeutics
05 Jul 2019
Executive Summary
Nasdaq-traded Apricus Biosciences Inc. agreed to merge with privately held CNS-focused start-up Seelos Therapeutics Inc. in an all-stock transaction in which Seelos receives Apricus shares amounting to Seelos stockholders having an expected 86% stake in the combined company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com